AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1326721 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymex L (100 mg 3 times a week, total dose 1800 mg, i.m.)
Number of subjects: 0
Study 1326721 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (60 Gy in 30 fractions)
Number of subjects: 0
Study 3919028 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphosphonate
Number of subjects: 177
Study 3919028 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no drug therapy (Control)
Number of subjects: 177
Study 30764702 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Cardiac Rehabilitation (exercise plus education)
Number of subjects: 115
Study 30764702 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only Cardiac Rehabilitation
Number of subjects: 115
Study 30764702 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 115
Study 29512827 — intervention group
Group type: EXPERIMENTAL
Intervention: 170 μg LPP administered subcutaneously over 3 weeks
Number of subjects: 554
Study 29512827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 26694502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball handle with the cable between the index and middle fingers (BallIM)
Number of subjects: 0
Study 26694502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball handle with the cable between the middle and ring fingers (BallMR)
Number of subjects: 0
Study 26694502 — intervention group
Group type: COMPARATOR
Intervention: Standard handle (StandH)
Number of subjects: 0
Study 26694502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball handle conditions (BallIM and BallMR)
Number of subjects: 0
Study 24606070 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (high or low physiological dose)
Number of subjects: 12
Study 24606070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21908133 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate and volume adjusted BVM (RVBVM)
Number of subjects: 52
Study 21908133 — intervention group
Group type: COMPARATOR
Intervention: Volume marked BVM (VBVM)
Number of subjects: 52
Study 20354566 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 2627
Study 20354566 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2627
Study 20354566 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARBs
Number of subjects: 2627
Study 20354566 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2627
Study 17684894 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 6
Study 17684894 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (control)
Number of subjects: 6
Study 16236939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 78
Study 16236939 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MT)
Number of subjects: 78
Study 11372586 — intervention group
Group type: EXPERIMENTAL
Intervention: Napsagatran (80 micrograms/min) + Warfarin (25 mg)
Number of subjects: 12
Study 11372586 — intervention group
Group type: COMPARATOR
Intervention: Napsagatran (80 micrograms/min)
Number of subjects: 12
Study 9732921 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg and amoxicillin 1 g, both given twice daily for 2 weeks (OA)
Number of subjects: 1000
Study 9732921 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily, clarithromycin 500 mg twice daily, and metronidazole 400 mg twice daily for 1 week (OCM)
Number of subjects: 1000
Study 7994673 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon with 0.5% timolol drops postoperatively (12 patients)
Number of subjects: 50
Study 7994673 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon with acetazolamide postoperatively (16 patients)
Number of subjects: 50
Study 7994673 — intervention group
Group type: COMPARATOR
Intervention: Healon only (12 patients)
Number of subjects: 50
Study 7994673 — intervention group
Group type: COMPARATOR
Intervention: No viscoelastic (10 patients)
Number of subjects: 50
Study 3141099 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glyburide combination therapy
Number of subjects: 64
Study 31329507 — intervention group
Group type: COMPARATOR
Intervention: Complex decongestive physiotherapy (CDP)
Number of subjects: 32
Study 31329507 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decongestive physiotherapy (CDP) + Kinesio Taping (KT)
Number of subjects: 32
Study 28974203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin administered prior to skin incision
Number of subjects: 1106
Study 28974203 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin administered after cord clamping
Number of subjects: 1106
Study 25846340 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Number of subjects: 52
Study 22757968 — intervention group
Group type: EXPERIMENTAL
Intervention: External Qigong Therapy (EQT)
Number of subjects: 101
Study 22757968 — intervention group
Group type: COMPARATOR
Intervention: Sham EQT
Number of subjects: 101
Study 20838775 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 10
Study 20838775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20838775 — intervention group
Group type: EXPERIMENTAL
Intervention: DAMP (20 mg/70 kg)
Number of subjects: 10
Study 20838775 — intervention group
Group type: COMPARATOR
Intervention: Placebo DAMP
Number of subjects: 10
Study 19083679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dellagrotte core-integration intervention over 2 months
Number of subjects: 27
Study 19083679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study 16868151 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (P)
Number of subjects: 40
Study 16868151 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (E2)
Number of subjects: 40
Study 16868151 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (E2) + Progesterone (P)
Number of subjects: 40
Study 16868151 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 40
Study 12439626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (450 mg/day)
Number of subjects: 7
Study 12439626 — intervention group
Group type: COMPARATOR
Intervention: Placebo Nefazodone (0 mg/day)
Number of subjects: 7
Study 10856143 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg combined with fluticasone 100 microg (combination product)
Number of subjects: 356
Study 10856143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 10856143 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 356
Study 10856143 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 100 microg
Number of subjects: 356
Study 9146330 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 70
Study 9146330 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 70
Study 9146330 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and Digoxin
Number of subjects: 70
Study 7974906 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of EP (Etoposide and Cisplatin) for good-risk GCT patients
Number of subjects: 0
Study 7974906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus ifosfamide (VIP, VeIP) and high-dose carboplatin and etoposide with AUBMT for poor-risk GCT patients
Number of subjects: 0
Study 7974906 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel in combination chemotherapy regimens
Number of subjects: 0
Study 2836295 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive case management (ACM)
Number of subjects: 167
Study 2836295 — intervention group
Group type: COMPARATOR
Intervention: Control group (eligible to receive all other aftercare services)
Number of subjects: 167
Study 30852432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention teaching about psychology of burnout, stress, coping with patient death, and managing distress
Number of subjects: 227
Study 30852432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 227
Study 28342911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute anaphylaxis
Number of subjects: 31
Study 28342911 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-induced allergic reactions
Number of subjects: 31
Study 27312330 — intervention group
Group type: EXPERIMENTAL
Intervention: Small reamer
Number of subjects: 100
Study 27312330 — intervention group
Group type: COMPARATOR
Intervention: Bone chisel
Number of subjects: 100
Study 24178907 — intervention group
Group type: EXPERIMENTAL
Intervention: HILT plus exercise (HILT + EX)
Number of subjects: 72
Study 24178907 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser plus exercise (PL + EX)
Number of subjects: 72
Study 24178907 — intervention group
Group type: EXPERIMENTAL
Intervention: HILT alone
Number of subjects: 72
Study 21963761 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) applied to the unlesioned pharyngeal cortex
Number of subjects: 18
Study 21963761 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) applied to the unaffected pharyngeal cortex in patients with chronic dysphagia
Number of subjects: 18
Study 21963761 — intervention group
Group type: COMPARATOR
Intervention: Sham PAS
Number of subjects: 18
Study 20506785 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of pleural tent (group 1)
Number of subjects: 60
Study 20506785 — intervention group
Group type: COMPARATOR
Intervention: No pleural tent (group 2)
Number of subjects: 60
Study 17643436 — intervention group
Group type: EXPERIMENTAL
Intervention: PHOPDT (Photodynamic therapy with Photofrin)
Number of subjects: 208
Study 17643436 — intervention group
Group type: COMPARATOR
Intervention: OM (Omeprazole only)
Number of subjects: 208
Study 17643436 — intervention group
Group type: EXPERIMENTAL
Intervention: PHOPDT
Number of subjects: 208
Study 17643436 — intervention group
Group type: COMPARATOR
Intervention: OM
Number of subjects: 208
Study 15105183 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled intervention aimed at increasing fruit and vegetable consumption for 1 month
Number of subjects: 157
Study 15105183 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled intervention aimed at increasing fruit and vegetable consumption for 1 year
Number of subjects: 157
Study 15105183 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline consumption of fruits
Number of subjects: 157
Study 15105183 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline consumption of vegetables
Number of subjects: 157
Study 15105183 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in fruit consumption
Number of subjects: 157
Study 15105183 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in vegetable consumption
Number of subjects: 157
Study 15105183 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 11999592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block with 25 mL mepivacaine 2% (15 mL for femoral nerve, 10 mL for sciatic nerve)
Number of subjects: 40
Study 11999592 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic with continuous intravenous infusion of remifentanil (0.1-0.3 microgkg(‐1) min(‐1)) and propofol (target plasma concentration 2-4 microg mL(‐1))
Number of subjects: 40
Study 11999592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block
Number of subjects: 40
Study 11999592 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 40
Study 9657355 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg p.o.)
Number of subjects: 8
Study 9657355 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (i.v. infusion for 60 min at doses of 4, 8, and 16 ng/kg/min)
Number of subjects: 8
Study 9657355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7616840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (15-minute test including 5 minutes of increasing workload followed by 10 minutes at 85% of maximal heart rate)
Number of subjects: 7
Study 2589861 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-85095
Number of subjects: 0
Study 2589861 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-21314
Number of subjects: 0
Study 2589861 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol 17-propionate
Number of subjects: 0
Study 2589861 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide
Number of subjects: 0
Study 330302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g, three times daily for 3 weeks)
Number of subjects: 16
Study 330302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 330302 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (dietary restriction and ad libitum antacid)
Number of subjects: 16
Study 6119939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg of morphine (postoperative)
Number of subjects: 404
Study 6119939 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of pethidine (postoperative)
Number of subjects: 404
Study 6119939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg of fentanyl (postoperative)
Number of subjects: 404
Study 6119939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg of morphine (peroperative)
Number of subjects: 404
Study 6119939 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl (peroperative)
Number of subjects: 404
Study 6119939 — intervention group
Group type: EXPERIMENTAL
Intervention: epidural injection of morphine after neuroleptoanaesthesia
Number of subjects: 404
Study 31135084 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a for 48 weeks
Number of subjects: 133
Study 31135084 — intervention group
Group type: COMPARATOR
Intervention: HBV DNA and qHBsAg decline at week 12
Number of subjects: 133
Study 28823835 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (up to 3mgs)
Number of subjects: 40
Study 26371360 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education and Support (DSMES)
Number of subjects: 124
Study 26371360 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study 23404948 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGBP) combined with omentectomy
Number of subjects: 20
Study 23404948 — intervention group
Group type: COMPARATOR
Intervention: Roux‐en‐Y gastric bypass (RYGBP) alone
Number of subjects: 20
Study 21558167 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning
Number of subjects: 0
Study 21558167 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory
Number of subjects: 0
Study 21558167 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 0
Study 21558167 — intervention group
Group type: EXPERIMENTAL
Intervention: Global mental status
Number of subjects: 0
Study 18953607 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained clinician ratings by speech-language pathologists (SLPs)
Number of subjects: 669
Study 18953607 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the 8-point Penetration/Aspiration Scale by SLPs
Number of subjects: 669
Study 17968815 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg administered 10 hours and 1.5 hours prior to nifedipine)
Number of subjects: 16
Study 17968815 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg) alone
Number of subjects: 16
Study 17968815 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg)
Number of subjects: 16
Study 17968815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and silymarin co-administration
Number of subjects: 16
Study 15156430 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily HAART
Number of subjects: 54
Study 15156430 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily HAART
Number of subjects: 54
Study 15156430 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 54
Study 15156430 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 54
Study 12168960 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis retinoic acid (13‐CRA)
Number of subjects: 28
Study 10553804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10553804 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-cream 0.05 g
Number of subjects: 50
Study 10553804 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-cream 0.10 g
Number of subjects: 50
Study 10553804 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-cream 0.15 g
Number of subjects: 50
Study 10553804 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-cream 0.20 g
Number of subjects: 50
Study 7598236 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA with 0.5% lidocaine and IV ketorolac (K)
Number of subjects: 60
Study 7598236 — intervention group
Group type: COMPARATOR
Intervention: IVRA with 0.5% lidocaine (control group)
Number of subjects: 60
Study 2119153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg IV bolus)
Number of subjects: 24
Study 2119153 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (50 micrograms/kg IV bolus followed by infusion at 1 micrograms.kg‐1.min‐1)
Number of subjects: 24
Study 2119153 — intervention group
Group type: COMPARATOR
Intervention: N2O-O2 (control group)
Number of subjects: 24
Study 710268 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (SST)
Number of subjects: 24
Study 710268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR)
Number of subjects: 24
Study 710268 — intervention group
Group type: COMPARATOR
Intervention: Traditional supportive therapy (TST)
Number of subjects: 24
Study 31079028 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 37
Study 31079028 — intervention group
Group type: COMPARATOR
Intervention: Control group (mood stabilizers included)
Number of subjects: 37
Study 28470371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 64
Study 25336357 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased radio frequency (pRF) ablation
Number of subjects: 76
Study 25336357 — intervention group
Group type: COMPARATOR
Intervention: Irrigated radio frequency (iRF) ablation
Number of subjects: 76
Study 24089054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (1 g/d)
Number of subjects: 52
Study 24089054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22155673 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention comprising 4 sessions of tailored motivational messages and self-regulation support (n = 324)
Number of subjects: 517
Study 22155673 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group (n = 179)
Number of subjects: 517
Study 19786674 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for diabetes medication choice
Number of subjects: 85
Study 19786674 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study 16679275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (CNR > 35.86)
Number of subjects: 35
Study 16679275 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton MRS (choline/creatine ratio > 1.56)
Number of subjects: 35
Study 16679275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model (CNR, choline/creatine ratio, presence of lactates)
Number of subjects: 35
Study 15246627 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC2 anti-idiotypic monoclonal antibody vaccine (2.5 microg - 10 mg)
Number of subjects: 50
Study 15246627 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC2 anti-idiotypic monoclonal antibody vaccine (lower three dose levels)
Number of subjects: 50
Study 15246627 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC2 anti-idiotypic monoclonal antibody vaccine (high doses)
Number of subjects: 50
Study 15246627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged booster immunizations
Number of subjects: 50
Study 12218721 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (70 mg genistin and daidzin per day)
Number of subjects: 75
Study 12218721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12218721 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract
Number of subjects: 75
Study 9584874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 25
Study 9584874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7619676 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan (5-HTP)
Number of subjects: 6
Study 7619676 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP)
Number of subjects: 6
Study 11527139 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234
Study 11527139 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 3234
Study 362297 — intervention group
Group type: EXPERIMENTAL
Intervention: testololactone
Number of subjects: 91
Study 362297 — intervention group
Group type: EXPERIMENTAL
Intervention: drostanolone
Number of subjects: 91
Study 362297 — intervention group
Group type: EXPERIMENTAL
Intervention: nandrolone
Number of subjects: 91
Study 362297 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide (additional treatment during second interval)
Number of subjects: 91
Study 30368163 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-195 800 mg added to ongoing ADT
Number of subjects: 234
Study 30368163 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ongoing ADT
Number of subjects: 234
Study 26730569 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART
Number of subjects: 88
Study 26730569 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Treatment Interruption (PTI)
Number of subjects: 88
Study 25298577 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RSP)
Number of subjects: 64